2023
Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists
Madanat Y, Zeidan A. Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists. Clinics In Laboratory Medicine 2023, 43: 685-698. PMID: 37865511, DOI: 10.1016/j.cll.2023.07.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBone marrow biopsy reportsAvailable treatment optionsBest therapeutic approachClinical presentationPathologic findingsRisk stratificationTherapeutic optionsTreatment optionsBiopsy reportsDisease entityTherapeutic approachesTreatment considerationsAccurate diagnosisGenetic abnormalitiesDiagnosisDisease subclassificationPatientsNeoplasmsHematopathologistsOptionsPrognosticationAbnormalitiesCliniciansSubclassificationEverolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer
Li G, Hu J, Cho C, Cui J, Li A, Ren P, Zhou J, Wei W, Zhang T, Liu X, Liu W. Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer. Cellular Signalling 2023, 109: 110729. PMID: 37257766, DOI: 10.1016/j.cellsig.2023.110729.Peer-Reviewed Original ResearchConceptsT cell tumor infiltrationTriple-negative breast cancerCD8+ T cell tumor infiltrationBreast cancerTumor infiltrationLack of target receptorsAnti-PD-1 antibodyAggressive subtype of breast cancerModels of triple-negative breast cancerSubtypes of breast cancerPD-L1 expressionEstrogen-positive breast cancerMTOR inhibitor everolimusPositive breast cancerProgression of triple-negative breast cancerReduced tumor growthAvailable treatment optionsCombination treatment strategiesPromote cancer cell survivalTreatment of estrogen-positive breast cancerAttenuate tumor progressionNonspecific cytotoxic agentsCancer cell survivalVascular endothelial cellsPotential therapeutic strategy
2022
Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management
Daniele S, Kim S, Grada A, Moore A, Suozzi K, Bunick C. Truncal Acne and Scarring: A Comprehensive Review of Current Medical and Cosmetic Approaches to Treatment and Patient Management. American Journal Of Clinical Dermatology 2022, 24: 199-223. PMID: 36539678, DOI: 10.1007/s40257-022-00746-4.Peer-Reviewed Original ResearchConceptsTruncal acne vulgarisAcne vulgarisTruncal acneHalf of patientsFacial acne vulgarisSignificant psychosocial burdenAvailable treatment optionsCommon skin disorderTreatment guidelinesPsychosocial burdenTreatment optionsTruncal involvementPatient managementFacial lesionsClinical problemSkin disordersUpper armCosmetic approachSebaceous glandsCurrent MedicalSkin areasPatientsAcneFocused reviewFurther investigationHigh-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Freeman L, Longbrake E, Coyle P, Hendin B, Vollmer T. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis. CNS Drugs 2022, 36: 1285-1299. PMID: 36350491, PMCID: PMC9645316, DOI: 10.1007/s40263-022-00965-7.Peer-Reviewed Original ResearchConceptsRelapsing-remitting multiple sclerosisHigh-efficacy therapiesMultiple sclerosisClinical benefitEarly treatmentRecent international consensus guidelinesLong-term clinical outcomesAvailable treatment optionsInternational consensus guidelinesTreatment-naïve individualsMechanism of actionDMT optionsMS careDisease courseClinical outcomesConsensus guidelinesTherapy optionsTreatment optionsNeurological damageTreatment strategiesEscalation approachClinical practiceUS FoodDrug AdministrationPatientsHigh Altitude Induced Thrombosis: Challenges and Recent Advancements in Pathogenesis and Management
Tyagi T, Jain K. High Altitude Induced Thrombosis: Challenges and Recent Advancements in Pathogenesis and Management. 2022, 85-101. DOI: 10.1007/978-981-19-1008-1_6.ChaptersMolecular pathogenesisAvailable treatment optionsBlood clot formationPulmonary embolismVenous thrombosisTreatment optionsClinical managementRisk factorsAnimal studiesHigh-altitude hypoxic environmentClot formationSerious disorderPathogenesisThrombosisHypoxic environmentVTEDisordersNumber of humanEmbolismCorrection to: Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families
Banerjee I, Raskin J, Arnoux JB, De Leon DD, Weinzimer SA, Hammer M, Kendall DM, Thornton PS. Correction to: Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and families. Orphanet Journal Of Rare Diseases 2022, 17: 205. PMID: 35585549, PMCID: PMC9118786, DOI: 10.1186/s13023-022-02363-0.Peer-Reviewed Original ResearchBlood sugar levelsBlood sugarLow blood sugarCongenital hyperinsulinismTreatment optionsBrain damageRare diseaseUnmet needLow blood sugar levelsSugar levelsLimited treatment optionsAvailable treatment optionsSpecialized treatment centersBest possible treatmentPerspectives of patientsQuick referralNew medicationsHealthy personsNewborn babiesSide effectsAbnormal releaseBetter outcomesTreatment centersPossible treatmentDevelopmental delay
2021
Mendelian Randomization in Stroke: A Powerful Approach to Causal Inference and Drug Target Validation
Acosta JN, Szejko N, Falcone GJ. Mendelian Randomization in Stroke: A Powerful Approach to Causal Inference and Drug Target Validation. Frontiers In Genetics 2021, 12: 683082. PMID: 34456968, PMCID: PMC8387928, DOI: 10.3389/fgene.2021.683082.Peer-Reviewed Original ResearchMendelian randomizationCardiovascular risk factorsRisk of strokeAvailable treatment optionsInflammation-related mechanismsIschemic strokeHemorrhagic strokeTreatment optionsRisk factorsLeading causeCurrent evidenceTherapeutic targetStrokeMR studiesNovel biological pathwaysDrug repurposingDrug developmentDrug target validationRandomizationTarget validationExposureBiological pathwaysCausal relationshipDiseaseUnmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists
Strober B, Kotowsky N, Medeiros R, Mackey R, Harrold L, Valdecantos W, Flack M, Golembesky A, Lebwohl M. Unmet Medical Needs in the Treatment and Management of Generalized Pustular Psoriasis Flares: Evidence from a Survey of Corrona Registry Dermatologists. Dermatology And Therapy 2021, 11: 529-541. PMID: 33638115, PMCID: PMC8018987, DOI: 10.1007/s13555-021-00493-0.Peer-Reviewed Original ResearchGPP flaresTreatment optionsPustular psoriasis flareAvailable treatment optionsChronic autoinflammatory diseaseStandard of careUnmet medical needNeutrophilic pustulesSteroid withdrawalPustular psoriasisPsoriasis flareConsensus guidelinesEffective therapyAutoinflammatory diseasesDiagnostic criteriaCurrent unmetConclusionThis surveyMedical needNew flareNatural historyMost dermatologistsDermatologistsTreatmentPustulesLimited information
2020
A Clinician's Guide to the Treatment of Endometriosis with Elagolix
Leyland N, Estes SJ, Lessey BA, Advincula AP, Taylor HS. A Clinician's Guide to the Treatment of Endometriosis with Elagolix. Journal Of Women's Health 2020, 30: 569-578. PMID: 32975461, PMCID: PMC8064963, DOI: 10.1089/jwh.2019.8096.Peer-Reviewed Original ResearchConceptsEndometriosis-associated painQuality of lifeGonadotropin-releasing hormone receptor antagonistBaseline clinical factorsModulation of estradiolIntolerable side effectsNew oral therapiesTreatment of endometriosisAvailable treatment optionsHormone receptor antagonistIndividualization of treatmentHypoestrogenic effectsRescue analgesicsPelvic painGnRH agonistOral therapyClinical factorsPain managementClinical evidenceTreatment optionsDosing optionsReceptor antagonistInsufficient efficacyClinician's GuideSide effectsAchieving Mental Health Equity: Addictions
Jordan A, Mathis ML, Isom J. Achieving Mental Health Equity: Addictions. Psychiatric Clinics Of North America 2020, 43: 487-500. PMID: 32773076, DOI: 10.1016/j.psc.2020.05.007.Peer-Reviewed Original Research
2019
Management of Hyperlipidemia After Stroke
Brooks DC, Schindler JL. Management of Hyperlipidemia After Stroke. Current Treatment Options In Cardiovascular Medicine 2019, 21: 93. PMID: 31840196, DOI: 10.1007/s11936-019-0774-8.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsManagement of hyperlipidemiaKey therapeutic targetCardiovascular diseaseTherapeutic targetAggressive LDL-C reductionStroke risk reductionLDL-C reductionAtherosclerotic vascular diseaseAvailable treatment optionsGeneral cardiovascular diseaseRecent FindingsStatinsIschemic strokePCSK9 inhibitorsHemorrhagic strokeRisk modificationTreatment optionsVascular diseaseRecent trialsNovel agentsNew agentsMost subtypesHyperlipidemiaStrokePatientsDisease
2018
Role of interventional radiology in the management of hepatocellular carcinoma: current status.
Holzwanger DJ, Madoff DC. Role of interventional radiology in the management of hepatocellular carcinoma: current status. Chinese Clinical Oncology 2018, 7: 49. PMID: 30180753, DOI: 10.21037/cco.2018.07.04.Peer-Reviewed Original ResearchConceptsEarly-stage diseaseStage diseaseHepatocellular carcinomaBarcelona Clinic Liver CancerIntermediate-grade diseaseGold standard therapyTrans-arterial chemoembolizationAvailable treatment optionsTreatment of patientsAdequate oncologic controlAdvanced diseaseLiver transplantationPalliative interventionsPerformance statusStandard therapySurgical resectionGrade diseaseOncologic controlLiver functionTreatment optionsRadiofrequency ablationEffective therapyLiver cancerBetter outcomesClinical practicePrimary hepatic neuroendocrine carcinoma: report of two cases and literature review
Zhao ZM, Wang J, Ugwuowo UC, Wang L, Townsend JP. Primary hepatic neuroendocrine carcinoma: report of two cases and literature review. BMC Clinical Pathology 2018, 18: 3. PMID: 29507528, PMCID: PMC5831736, DOI: 10.1186/s12907-018-0070-7.Peer-Reviewed Case Reports and Technical NotesTranscatheter arterial chemoembolizationTreatment optionsLiver biopsyNeuroendocrine carcinomaSomatostatin analoguesLiver protectionLiver lobeNon-hepatic originHepatic hilar lymph nodesSmall cell neuroendocrine carcinomaHepatic neuroendocrine carcinomaIneffective treatment optionsSymptoms of jaundiceInitial hospital admissionHilar lymph nodesSurvival of patientsLimited treatment optionsRight liver lobeUnique clinical featuresAvailable treatment optionsHepatic portal veinAbdominal painLiver transplantSurgical resectionArterial chemoembolization
2017
Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease
Bakshi N, Sinha C, Ross D, Khemani K, Loewenstein G, Krishnamurti L. Proponent or collaborative: Physician perspectives and approaches to disease modifying therapies in sickle cell disease. PLOS ONE 2017, 12: e0178413. PMID: 28727801, PMCID: PMC5518995, DOI: 10.1371/journal.pone.0178413.Peer-Reviewed Original ResearchConceptsSickle cell diseaseChronic blood transfusionsBone marrow transplantationDisease-modifying therapiesTreatment-related decisionsTreatment optionsCell diseasePhysician perspectivesAvailable disease-modifying therapiesLong-term adverse effectsPhysician-related factorsAvailable treatment optionsDisease-related factorsPossible treatment optionsPatients/familiesInherited blood disorderBlood transfusionMarrow transplantationPhysician interviewsPatient burdenPhysicians' perceptionsPatient's perspectivePhysicians' approachPatient engagementTreatment planOS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143
Reardon D, Omuro A, Brandes A, Rieger J, Wick A, Sepulveda J, Phuphanich S, de Souza P, Ahluwalia M, Lim M, Vlahovic G, Sampson J. OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143. Neuro-Oncology 2017, 19: iii21-iii21. PMCID: PMC5463583, DOI: 10.1093/neuonc/nox036.071.Peer-Reviewed Original ResearchObjective response rateTreatment-related AEsProgression-free survivalOverall survivalRecurrent glioblastomaSerious AEsMeasurable diseaseOS ratesInvestigator-assessed progression-free survivalCommon treatment-related AEsHuman IgG4 monoclonal antibodyOnly serious AESafety of nivolumabMedian overall survivalNeuro-Oncology criteriaSecond-line settingDeath-1 receptorSingle-agent therapyAvailable treatment optionsMalignant neoplasm progressionIgG4 monoclonal antibodyMultiple cancer typesCheckMate 143Evaluable ptsImproved OSBurden and Management of Multidrug-Resistant Organisms in Palliative Care
Datta R, Juthani-Mehta M. Burden and Management of Multidrug-Resistant Organisms in Palliative Care. Palliative Care And Social Practice 2017, 10: 1178224217749233. PMID: 29317826, PMCID: PMC5753884, DOI: 10.1177/1178224217749233.Peer-Reviewed Original ResearchMultidrug-resistant organismsPalliative careTerminal illnessGoals of palliationPalliative care patientsPalliative care settingAvailable treatment optionsInfection prevention measuresQuality of lifeCommon complicationContact precautionsMetastatic diseaseCare patientsPatient isolationTreatment optionsSymptom assessmentCare discussionsAntimicrobial therapyCommon signsCare settingsCognitive impairmentPsychological burdenPatientsInfectionAdverse effects
2015
Gamma knife stereotactic radiosurgical thalamotomy for intractable tremor: A systematic review of the literature
Campbell AM, Glover J, Chiang VL, Gerrard J, Yu JB. Gamma knife stereotactic radiosurgical thalamotomy for intractable tremor: A systematic review of the literature. Radiotherapy And Oncology 2015, 114: 296-301. PMID: 25690750, DOI: 10.1016/j.radonc.2015.01.013.Peer-Reviewed Original ResearchConceptsStereotactic radiosurgical thalamotomyRadiosurgical thalamotomyIntractable tremorSystematic reviewUnilateral gamma knife thalamotomyOnly available treatment optionGamma knife thalamotomyAvailable treatment optionsSignificant psychological burdenQuality of lifeSurgical candidatesSevere complicationsSurgical treatmentMedical therapyTransient hemiparesisAdverse outcomesTreatment optionsPatient deathStereotactic radiosurgical techniquesMovement disordersLanguage of publicationStereotactic radiosurgeryTreatment efficacyPsychological burdenRadiosurgical techniques
2009
Racial Disparities in Treatment Preferences for Rheumatoid Arthritis
Constantinescu F, Goucher S, Weinstein A, Fraenkel L. Racial Disparities in Treatment Preferences for Rheumatoid Arthritis. Medical Care 2009, 47: 350-355. PMID: 19165120, PMCID: PMC3682220, DOI: 10.1097/mlr.0b013e31818af829.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntirheumatic AgentsArthritis, RheumatoidBlack or African AmericanCommunicationDecision MakingDistrict of ColumbiaFemaleHealth Knowledge, Attitudes, PracticeHealthcare DisparitiesHumansInterviews as TopicMaleMedication AdherenceMethotrexateMiddle AgedOutpatient Clinics, HospitalPatient SatisfactionPsychometricsRheumatologySocioeconomic FactorsSoftwareTumor Necrosis Factor-alphaVirginiaWhite PeopleYoung AdultConceptsAggressive therapyRheumatoid arthritisTreatment preferencesAggressive treatmentChronic diseasesRacial disparitiesConsecutive eligible patientsLong-term outcomesAvailable treatment optionsBest available treatment optionsImportant clinical implicationsSimilar disease severityEligible patientsWhite patientsBlack patientsTreatment optionsUnadjusted analysesPatient preferencesPhysician communicationPatient educationPatientsDisease severityMedical interventionsClinical implicationsTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply